Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 1
2002 1
2004 1
2007 1
2008 2
2009 6
2010 7
2011 6
2012 5
2013 6
2014 16
2015 20
2016 18
2017 22
2018 33
2019 47
2020 49
2021 42
2022 58
2023 50
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.
Stemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A, Ben-Ami R, Ráčil Z, Piechotta V, Lewis R, Cornely OA. Stemler J, et al. Lancet Haematol. 2022 May;9(5):e361-e373. doi: 10.1016/S2352-3026(22)00073-4. Lancet Haematol. 2022. PMID: 35483397 Review.
For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia, monotherapy, and combination with chemotherapy. Antifungal prophylaxis is …
For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with re …
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M, Fernandez C, Hauch O, Klibanov OM, Chaudhary T, Rives V. Heuser M, et al. Future Oncol. 2023 Apr;19(11):789-810. doi: 10.2217/fon-2022-1286. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170899 Free article. Review.
Aim: To review clinical evidence for current and emerging treatments for patients with acute myeloid leukemia (AML) who are ineligible for first-line induction chemotherapy. ...Conclusion: Targeted therapy combined with a HMA shows the most promising results …
Aim: To review clinical evidence for current and emerging treatments for patients with acute myeloid leukemia (AML) who …
Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies.
Larsson SC, Burgess S. Larsson SC, et al. EBioMedicine. 2022 Aug;82:104154. doi: 10.1016/j.ebiom.2022.104154. Epub 2022 Jul 8. EBioMedicine. 2022. PMID: 35816897 Free PMC article.
FINDINGS: Meta-analyses of findings of 29 published MR studies and 123 de novo MR analyses of 57 distinct primary outcomes showed that genetic liability to smoking (smoking initiation or lifetime smoking) was associated with increased risk of 13 circulatory system diseases, sever …
FINDINGS: Meta-analyses of findings of 29 published MR studies and 123 de novo MR analyses of 57 distinct primary outcomes showed that genet …
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Short NJ, et al. JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. JAMA Oncol. 2020. PMID: 33030517 Free PMC article.
IMPORTANCE: Measurable residual disease (MRD) refers to neoplastic cells that cannot be detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia (AML), determining the association of MRD with survival may improve prognostication …
IMPORTANCE: Measurable residual disease (MRD) refers to neoplastic cells that cannot be detected by standard cytomorphologic analysis. In pa …
Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Ramsingh G. Daver NG, et al. J Hematol Oncol. 2023 Mar 6;16(1):19. doi: 10.1186/s13045-023-01417-5. J Hematol Oncol. 2023. PMID: 36879351 Free PMC article.
BACKGROUND: TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. ...
BACKGROUND: TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associate …
The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis.
Du Y, Li C, Yan J. Du Y, et al. Hematology. 2023 Dec;28(1):2198098. doi: 10.1080/16078454.2023.2198098. Hematology. 2023. PMID: 37036307
OBJECTIVES: The meta-analysis sought to evaluate the efficacy and safety of a combination of venetoclax (Ven) and azacitidine (AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ...
OBJECTIVES: The meta-analysis sought to evaluate the efficacy and safety of a combination of venetoclax (Ven) and azacitidine (AZA) in the t …
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Smith TJ, et al. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169616 Review.
The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults. RECOMMENDATIONS: Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febr …
The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic …
A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS, Ghazi H, Fletcher DM, Guinn BA. Morris VS, et al. Int J Mol Sci. 2023 Jun 2;24(11):9667. doi: 10.3390/ijms24119667. Int J Mol Sci. 2023. PMID: 37298623 Free PMC article. Review.
Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. ...This organized the antigens according to their potential to act as targets fo …
Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation …
Early Life Nutrition Factors and Risk of Acute Leukemia in Children: Systematic Review and Meta-Analysis.
Kintossou AK, Blanco-Lopez J, Iguacel I, Pisanu S, Almeida CCB, Steliarova-Foucher E, Sierens C, Gunter MJ, Ladas EJ, Barr RD, Van Herck K, Kozlakidis Z, Huybrechts I. Kintossou AK, et al. Nutrients. 2023 Aug 29;15(17):3775. doi: 10.3390/nu15173775. Nutrients. 2023. PMID: 37686807 Free PMC article. Review.
Acute leukemia commonly occurs in young children with peak incidence at the age of 2-5 years. ...Further research into the potential role of diet in early life and the risk of acute leukemia is needed to develop prevention strategies at population leve …
Acute leukemia commonly occurs in young children with peak incidence at the age of 2-5 years. ...Further research into the pot …
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Shahzad M, et al. Front Immunol. 2023 Apr 24;14:1152457. doi: 10.3389/fimmu.2023.1152457. eCollection 2023. Front Immunol. 2023. PMID: 37168849 Free PMC article. Review.
BACKGROUND: We conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML). METHODS: We performed a literature search on PubMed, Cochran …
BACKGROUND: We conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) thera …
368 results